Similar articles

• Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

  Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP; Scleroderma Lung Study Research Group. Strange C, et al. Am J Respir Crit Care Med. 2008 Jan 1;177(1):91-8. doi: 10.1164/rccm.200705-655OC. Epub 2007 Sep 27. Am J Respir Crit Care Med. 2008. PMID: 17901414 Free PMC article. Clinical Trial.
• Gene expression in bronchoalveolar lavage cells from scleroderma patients.

  Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Luzina IG, et al. Am J Respir Cell Mol Biol. 2002 May;26(5):549-57. doi: 10.1165/ajrcmb.26.5.4683. Am J Respir Cell Mol Biol. 2002. PMID: 11970906
• Cyclophosphamide versus placebo in scleroderma lung disease.

  Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Tashkin DP, et al. N Engl J Med. 2006 Jun 22;354(25):2655-66. doi: 10.1056/NEJMoa055120. N Engl J Med. 2006. PMID: 16790698 Clinical Trial.
• Evaluation and management of pulmonary fibrosis in scleroderma.

  White B. White B. Curr Rheumatol Rep. 2002 Apr;4(2):108-12. doi: 10.1007/s11926-002-0005-1. Curr Rheumatol Rep. 2002. PMID: 11890875 Review.
• Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.

  Vallance DK, Lynch JP 3rd, McCune WJ. Vallance DK, et al. Curr Opin Rheumatol. 1995 May;7(3):174-82. doi: 10.1097/00002281-199505000-00004. Curr Opin Rheumatol. 1995. PMID: 7612408 Review.